Document Detail


Combination antiretroviral therapy including ritonavir in children infected with human immunodeficiency.
MedLine Citation:
PMID:  10207548     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To assess the efficacy of combination therapy that includes ritonavir in HIV-1 infected children. DESIGN: A monocentric retrospective study. PATIENTS AND METHODS: Twenty-two children with a minimum follow-up of 6 months under triple therapy including ritonavir were analysed for treatment efficacy. At entry, all the patients were protease inhibitor naive and all but two had received previous antiretroviral therapy during a median period of 5 years. Their initial median CD4+ lymphocyte count and viral load were 121 x 10(6)/l and 5.08 log10 copies/ml, respectively. Clinical and biological evaluation included clinical assessment every 6 weeks and determination of CD4 cell count and HIV-RNA concentration every 3 months. RESULTS: Median length of follow-up on triple therapy was 15 months (range: 7-21 months). Neither progression in the CDC classification nor death occurred. No significant change in mean weight SD scores was noted when baseline values were compared with values obtained after 1 year of triple therapy. Median CD4 count increases were of 210 x 10(6)/l, 415 x 10(6)/l, and 472 x 10(6)/l cells at 6, 12, and 18 months, respectively. Among the patients baseline characteristics, neither age nor initial CD4 cells count influenced the magnitude of immunologic improvement. There were median decreases of 1.14, 0.95, and 1.5 log10 per ml of plasma in the concentration of viral RNA at 6, 12, and 18 months respectively. Seven patients maintained an undetectable viral load when under treatment. The introduction of at least one new reverse transcriptase inhibitor at the initiation of triple therapy correlated significantly with a greater viral suppression. CONCLUSION: Despite variable viral response, antiretroviral-experienced HIV-infected children demonstrated a substantial CD4 cell increase during a median period of 15 months of ritonavir containing combination therapy.
Authors:
I Thuret; G Michel; H Chambost; C Tamalet; P Giraud; C Brunet; H Perrimond
Related Documents :
10540048 - Interferon alfa-2b alone or in combination with ketoprofen as treatment for interferon-...
11834948 - Usefulness of monitoring hiv drug resistance and adherence in individuals failing highl...
17159658 - Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance...
10048898 - Mycobacterial lymphadenitis associated with the initiation of combination antiretrovira...
10598708 - A randomized, controlled study of a programmable shunt valve versus a conventional valv...
8163368 - Subcutaneous sumatriptan in a clinical setting: the first 100 consecutive patients with...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  AIDS (London, England)     Volume:  13     ISSN:  0269-9370     ISO Abbreviation:  AIDS     Publication Date:  1999 Jan 
Date Detail:
Created Date:  1999-06-28     Completed Date:  1999-06-28     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8710219     Medline TA:  AIDS     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  81-7     Citation Subset:  IM; X    
Affiliation:
Service d'Hematologie Pédiatrique, CHU Timone, Marseille, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Anti-HIV Agents / adverse effects,  therapeutic use*
Child
Child, Preschool
Drug Therapy, Combination
Female
Follow-Up Studies
HIV Infections / drug therapy*,  immunology,  virology
HIV Protease Inhibitors / adverse effects,  therapeutic use*
Humans
Lamivudine / adverse effects,  therapeutic use
Male
Reverse Transcriptase Inhibitors / adverse effects,  therapeutic use*
Ritonavir / adverse effects,  therapeutic use*
Stavudine / adverse effects,  therapeutic use
Zidovudine / adverse effects,  therapeutic use
Chemical
Reg. No./Substance:
0/Anti-HIV Agents; 0/HIV Protease Inhibitors; 0/Reverse Transcriptase Inhibitors; 0/Ritonavir; 134678-17-4/Lamivudine; 30516-87-1/Zidovudine; 3056-17-5/Stavudine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 ...
Next Document:  Persistently negative HIV-1 antibody enzyme immunoassay screening results for patients with HIV-1 in...